Want to see SE:EXPRS2 full AI Analyst Report?
EXPRS2 Stock Chart & Stats
kr17.10
-kr1.20(-4.51%)
At close: 4:00 PM EST
kr17.10
-kr1.20(-4.51%)
Day’s Range― - ―
52-Week Rangekr1.22 - kr10.00
Previous CloseN/A
Volume135.00
Average Volume (3M)19.88K
Market Cap
kr33.81M
Enterprise Valuekr4.08
Total Cash (Recent Filing)kr21.84M
Total Debt (Recent Filing)kr1.25M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.33
Shares Outstanding23,398,983
10 Day Avg. Volume26,629
30 Day Avg. Volume19,883
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.27
Price to Sales (P/S)12.37
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.64
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Niche Protein Expression PlatformExpreS2's core platform targets technically challenging recombinant proteins and antigens, a specialized capability that creates higher barriers to entry and client stickiness. This technical differentiation supports durable demand from vaccine and antibody R&D programs that need expert manufacturing partners.
Low Financial LeverageVery low debt levels reduce short-term solvency risk and preserve flexibility to raise capital for R&D or partnerships. For an early-stage biotech with ongoing losses, modest leverage lessens forced deleveraging risk and supports strategic options like licensing or equity raises without heavy interest burdens.
Fee-for-service + Collaboration Revenue MixA fee-for-service model provides repeatable, project-based revenue streams tied to customers' R&D timelines, while collaborations can add milestone and royalty upside. This mix lets the company monetize platform expertise across multiple programs and reduces reliance on a single product outcome over the medium term.
Bears Say
Persistent Cash BurnSustained large negative operating cash flow implies continued financing needs and shortens runway absent new capital. Over time this increases dilution risk, constrains discretionary R&D or capacity investments, and forces management to prioritize near-term funding over long-term strategic initiatives.
Deeply Negative MarginsPersistent negative gross and operating margins indicate the current cost base is structurally misaligned with revenue scale. Unless margins improve via higher utilization, pricing power, or cost reductions, the business cannot become self-funding and remains dependent on external capital for continuity.
Small And Declining Revenue BaseA very small and falling revenue base limits operating leverage and the ability to absorb fixed R&D and production costs. Declining top-line suggests challenges winning or scaling customer programs, lengthening the path to breakeven and amplifying reliance on financing or partnership milestone payments.
EXPRS2 FAQ
What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?
ExpreS2ion Biotech Holding AB lowest stock price was kr1.22 and its highest was kr10.00 in the past 12 months.
What is ExpreS2ion Biotech Holding AB’s market cap?
ExpreS2ion Biotech Holding AB’s market cap is kr33.81M.
When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?
ExpreS2ion Biotech Holding AB’s upcoming earnings report date is Aug 20, 2026 which is in 26 days.
How were ExpreS2ion Biotech Holding AB’s earnings last quarter?
ExpreS2ion Biotech Holding AB released its earnings results on May 28, 2026. The company reported -kr0.97 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ExpreS2ion Biotech Holding AB overvalued?
According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued.
Does ExpreS2ion Biotech Holding AB pay dividends?
ExpreS2ion Biotech Holding AB does not currently pay dividends.
What is ExpreS2ion Biotech Holding AB’s EPS estimate?
ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ExpreS2ion Biotech Holding AB have?
ExpreS2ion Biotech Holding AB has 23,398,983 shares outstanding.
What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?
ExpreS2ion Biotech Holding AB reported an EPS of -kr0.97 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.301%.
Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?
Currently, no hedge funds are holding shares in SE:EXPRS2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ExpreS2ion Biotech Holding AB
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.